Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R. Vecchione L, et al. Among authors: chiron m. Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059. Cell. 2016. PMID: 27058664 Free article.
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Gauthier L, Virone-Oddos A, Beninga J, Rossi B, Nicolazzi C, Amara C, Blanchard-Alvarez A, Gourdin N, Courta J, Basset A, Agnel M, Guillot F, Grondin G, Bonnevaux H, Bauchet AL, Morel A, Morel Y, Chiron M, Vivier E. Gauthier L, et al. Among authors: chiron m. Nat Biotechnol. 2023 Sep;41(9):1296-1306. doi: 10.1038/s41587-022-01626-2. Epub 2023 Jan 12. Nat Biotechnol. 2023. PMID: 36635380 Free PMC article.
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
Lefebvre AM, Adam J, Nicolazzi C, Larois C, Attenot F, Falda-Buscaiot F, Dib C, Masson N, Ternès N, Bauchet AL, Demers B, Chadjaa M, Sidhu S, Combeau C, Soria JC, Scoazec JY, Naimi S, Angevin E, Chiron M, Henry C. Lefebvre AM, et al. Among authors: chiron m. Lung Cancer. 2023 Oct;184:107356. doi: 10.1016/j.lungcan.2023.107356. Epub 2023 Aug 26. Lung Cancer. 2023. PMID: 37660479 Free article.
Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
Chami B, Okuda M, Moayeri M, Pirenne F, Hidaka Y, Nambiar A, Song Z, Bedel O, Zhang B, Hopke J, Deng G, Zhu C, Macé S, Chiron M, Adrian F, Fukao T, Basile FG, Martin T. Chami B, et al. Among authors: chiron m. Transfusion. 2022 Nov;62(11):2334-2348. doi: 10.1111/trf.17137. Epub 2022 Oct 14. Transfusion. 2022. PMID: 36239134 Free PMC article.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S, Diallo BK, El-Murr N, Carrié N, Tang A, Fournier A, Bonnevaux H, Nicolazzi C, Cuisinier M, Arnould I, Sidhu SS, Corre J, Avet-Loiseau H, Teillaud JL, van de Velde H, Wiederschain D, Chiron M, Martinet L, Virone-Oddos A. Kassem S, et al. Among authors: chiron m. Blood. 2022 Feb 24;139(8):1160-1176. doi: 10.1182/blood.2021012448. Blood. 2022. PMID: 35201323 Free article.
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
Zucali PA, Lin CC, Carthon BC, Bauer TM, Tucci M, Italiano A, Iacovelli R, Su WC, Massard C, Saleh M, Daniele G, Greystoke A, Gutierrez M, Pant S, Shen YC, Perrino M, Meng R, Abbadessa G, Lee H, Dong Y, Chiron M, Wang R, Loumagne L, Lépine L, de Bono J. Zucali PA, et al. Among authors: chiron m. J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697. J Immunother Cancer. 2022. PMID: 35058326 Free PMC article. Clinical Trial.
97 results